Pharmacogenomics
Reduce trial and error in medicine with LifeBrite Labs’ pharmacogenomic testing. We apply the science of molecular genetic testing to enhance your practice of personalized medicine. Pharmacogenomics enables physicians to identify the best treatment course for a patient as quickly as possible.
With an understanding of each patient’s genetic profile, you can optimize drug selection and dosing. A one-time test gives you precision guidance for medications used in managing cardiovascular disease, mental disorders, pain, cancer, diabetes, gastrointestinal conditions, infectious disease, immune disorders, and urological conditions.
Many of the variations identified by pharmacogenomic testing center on the production of enzymes that metabolize drugs. Recommended medicine dosage is generally based on the metabolism of “extensive metabolizers.” Slow and intermediate metabolizers of a drug may experience more severe side effects and have a less effective therapeutic response. Ultrarapid metabolizers may metabolize the drug too quickly, making it difficult to maintain optimal drug levels in the body.
Pharmacogenomic testing uses genotyping to detect single nucleotide polymorphisms (SNPs) and copy number variations (CNVs) in several drug metabolizing enzyme (DME) genes. A physician can then utilize this information to select the most effective medicine and dosage for a patient to avoid adverse reactions.
LifeBrite Laboratories’ Pharmacogenomics Testing Includes:
Anti-Cancer Medications Panel
Drug Class | Drugs | Gene(s) Tested |
Antifolates | Methotrexate | MTHFR |
Detoxifying Agents | Rasburicase | G6PD |
Protein Kinase Inhibitors | Gefitinib, Dabrafenib | CYP2D6, G6PD |
Cardiovascular Medications Panel
Drug Class | Drugs | Gene(s) Tested |
Angiotensin II Receptor Antagonists | Azilsartan, Irbesartan, Losartan | CYP2C9 |
Antianginal Agents | Ranolazine | CYP2D6 |
Antiarrhythmics | Flecainide, Mexiletine Propafenone | CYP2D6 |
Anticoagulants | Warfarin | VKORC1, CYP2C9 |
Antiplatelets | Clopidogrel, Prasugrel | CYP2C19 |
Beta Blockers | Carvedilol, Metoprolol, Nebivolol, Propranolol, Timolol | CYP2D6 |
Diuretics | Torsemide | CYP2C9 |
Statins | Atorvastatin, Fluvastatin, Lovastatin, Pitavastatin, Pravastatin, Rosuvastatin, Simvastatin | CYP2C9, CYP3A4, SLCO1B1 |
Diabetes and Gastrointestinal Medications Panel
Drug Class | Drugs | Gene(s) Tested |
Meglitinides | Repaglinide, Nategliniden | CYP2C9, SLCO1B1 |
Sulfonylureas | Chlorpropamide, Glimepiride, Glipizide, Glyburide, Tolbutamide | CYP2C9 |
Antiemetics | Dolasetron, Dronabinol, Metoclopramide, Netupitant-Palonosetron, Ondansetron, Palonosetron | CYP2C9, CYP2D6 |
Proton Pump Inhibitors | Dexlansoprazole, Esomeprazole, Lansoprazole, Omeprazole, Pantoprazole, Rabeprazole | CYP2C19 |
Gaucher Disease | Eliglustat | CYP2D6 |
Immunology and Urology Medications Panel
Drug Class | Drugs | Gene(s) Tested |
Anti-gout Agents | Lesinurad, Pegloticase, Probenecid | CYP2C9, G6PD |
Immunomodulators | Leflunomide, Tofacitinib | CYP2C19 |
Cholinergic Agonists | Cevimeline | CYP2D6 |
Immunosuppressant | Tacrolimus | CYP3A5 |
Alpha-Blockers for Benign Prostatic | Tamsulosin | CYP2D6 |
Antispasmodics for Overactive Bladder | Darifenacin, Fesoterodine, Mirabegron, Tolterodine | CYP2D6 |
Infectious Disease Medications Panel
Drug Class | Drugs | Gene(s) Tested |
Antibiotics | Dapsone, Methylene blue, Nitrofurantoin, Sulfamethoxazole | G6PD |
Anti-HIV | Efavirenz | CYP2B6 |
Antifungals | Voriconazole | CYP2C19 |
Antimalarials | Proguanil, Chloroquine, Primaquine | CYP2C19, G6PD |
Pain Medications Panel
Drug Class | Drugs | Gene(s) Tested |
Muscle Relaxants | Tizanidine, Carisoprodol | CYP1A2, CYP2C19 |
Anesthetic | Propofol | CYP2B6 |
NSAIDs | Celecoxib, Diclofenac, Flurbiprofen, Ibuprofen, Indomethacin, Meloxicam, Piroxicam | CYP2C9 |
Opioids | Morphine, Methadone, Codeine, Dihydrocodeine, Hydrocodone, Oxycodone, Tramadol3, Fentanyl | COMT, CYP2B6, CYP2D6, OPRM1 |
Psychotropic Medications Panel
Drug Class | Drugs | Gene(s) Tested |
Antiaddictives | Bupropion, Methadone, Naltrexone | ANKK1, CYP2B6, OPRM1 |
Anti-ADHD Agents | Dexmethylphenidate, Methylphenidate, Amphetamine, Dextroamphetamine, Lisdexamfetamine, Atomoxetine1, Clonidine | ADRA2A, COMT, CYP2D6 |
Anticonvulsants | Brivaracetam, Lacosamide, Phenobarbital, Primidone, Zonisamide, Fosphenytoin, Phenytoin | CYP2C19, CYP2C9 |
Antidementia Agents | Donepezil, Galantamine | CYP2D6 |
Antidepressants | Amitriptyline, Amoxapine, Bupropion, Citalopram, Clomipramine, Desipramine, Desvenlafaxine, Doxepin, Duloxetine, Escitalopram, Fluoxetine, Fluvoxamine, Imipramine, Maprotiline, Mirtazapine, Nefazodone, Nortriptyline, Paroxetine, Protriptyline, Sertraline, Trimipramine, Venlafaxine Vortioxetine | ANKK1, CYP2B6, CYP2C19, CYP2D6, HTR2A |
Antipsychotics | Aripiprazole, Brexpiprazole, Chlorpromazine, Clozapine, Fluphenazine, Haloperidol, Iloperidone, Olanzapine, Paliperidone, Perphenazine, Pimozide, Risperidone, Tetrabenazine, Thioridazine | CYP1A2, CYP2D6, HTR2A |
Benzodiazepines | Clobazam, Diazepam, Lorazepam, Oxazepam | CYP2C19, UGT2B15 |
Other Neurological Agents | Dextromethorphan, Flibanserin | CYP2C19, CYP2D6 |
Condition | Gene Tested |
Antipsychotic-Induced Hyperprolactinemia, tardive dyskinesia and weight gain | ANKK1 |
Hyperhomocysteinemia | MTHFR |